SyMap Medical recently announced the successful financing of nearly $100 million from VMS Group and Primavera Capital, with participation from SiMiao Capital and HongShan Capital.

CEC Capital Group served as the exclusive financial advisor in this transaction.

As the largest single financing in the global RDN field to date, the proceeds from this round will be primarily used to accelerate the global clinical registration trials for multiple innovative medical device products by SyMap Medical. The funds will also support the research and development of next-generation RDN and groundbreaking respiratory intervention products, as well as acquisitions of overseas innovative technologies and product lines. The company aims to create an cutting-edge technology platform in the fields of hypertension, heart failure, arrhythmia, asthma, and early-stage lung cancer, positioning itself as a global leader in interventional treatments for cardiovascular and respiratory diseases.